Lumea lands No. 1,641 on Inc. 5000 list

Lumea ranked No. 1,641 on the 2026 Inc. 5000, up from No. 2,468 a year earlier, as the Lehi, Utah, digital pathology company posted continued revenue growth. The ranking underscores demand for accessible cancer diagnostics and places Lumea among the fastest-growing private companies in the U.S.

Why it matters: - Lumea’s rise on the Inc. 5000 signals sustained growth in digital pathology, a category tied to faster and more accessible cancer diagnostics. - The ranking can help validate Lumea’s position with customers, partners and investors in the healthcare technology market.

What happened: - Lumea ranked No. 1,641 on the 2026 Inc. 5000 list of America’s fastest-growing private companies. - The company also placed No. 38 among Utah businesses and No. 177 in the healthcare and medical industry. - Lumea moved up from No. 2,468 on last year’s list. - CEO James Thackeray said the jump reflects momentum behind Lumea’s mission to make quality cancer diagnostics accessible everywhere.

The details: - Inc. 5000 ranks companies by percentage revenue growth from 2022 to 2025. - To qualify, companies had to be founded and generating revenue by March 31, 2022. - Eligible companies had to be U.S.-based, privately held, for-profit and independent as of Dec. 31, 2025. - The minimum revenue threshold was $100,000 in 2022 and $2 million in 2025. - Inc. said the 2026 group reflects growth across AI, advanced manufacturing, healthcare, consumer products and professional services. - Among the 5,000 companies, the median three-year revenue growth rate was 130%. - The companies on the list have collectively added more than 627,208 jobs over the past three years. - The full list and searchable database are available here.

Between the lines: - Lumea’s ranking suggests its digital pathology tools are gaining traction in a competitive market where efficiency and lower costs matter. - The company’s focus on workflow-driven innovation and AI-enabled viewing fits broader healthcare trends toward automation and scale. - Inc. framed the list as a marker of entrepreneurship, resilience and job creation, not just revenue growth.

What's next: - Lumea is likely to keep leaning on the Inc. 5000 recognition as it expands its digital pathology business. - The company says it will continue investing in efficient, affordable digital pathology and building toward broader access to cancer diagnostics. - More information is available at Lumea Digital.